Vicarious Surgical Inc.

NYSE:RBOT Stock Report

Market Cap: US$71.8m

Vicarious Surgical Past Earnings Performance

Past criteria checks 0/6

Vicarious Surgical's earnings have been declining at an average annual rate of -35.8%, while the Medical Equipment industry saw earnings growing at 12% annually.

Key information

-35.8%

Earnings growth rate

22.1%

EPS growth rate

Medical Equipment Industry Growth8.9%
Revenue growth raten/a
Return on equity-107.8%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

We're Keeping An Eye On Vicarious Surgical's (NYSE:RBOT) Cash Burn Rate

Nov 30
We're Keeping An Eye On Vicarious Surgical's (NYSE:RBOT) Cash Burn Rate

Here's Why Vicarious Surgical (NYSE:RBOT) Must Use Its Cash Wisely

Aug 16
Here's Why Vicarious Surgical (NYSE:RBOT) Must Use Its Cash Wisely

Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Mar 05
Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Nov 24
Is Vicarious Surgical (NYSE:RBOT) In A Good Position To Invest In Growth?

Vicarious Surgical: Huge Potential But Low Margin Of Safety To Commercialization

Aug 24

Here's Why We're Watching Vicarious Surgical's (NYSE:RBOT) Cash Burn Situation

Jul 18
Here's Why We're Watching Vicarious Surgical's (NYSE:RBOT) Cash Burn Situation

Vicarious Surgical: Cash Burn Adds To Downside Risk

May 26

Vicarious Surgical Non-GAAP EPS of -$0.16 beats by $0.02

Feb 13

Vicarious Surgical Non-GAAP EPS of -$0.18 misses by $0.03

Nov 07

Vicarious Surgical Non-GAAP EPS of -$0.16 misses by $0.02

Aug 08

Vectoring In On Vicarious Surgical Inc.

Jun 23

Vicarious Surgical: Developing Minimally Invasive VR Surgical System

Nov 29

Revenue & Expenses Breakdown

How Vicarious Surgical makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NYSE:RBOT Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-622739
30 Jun 240-612842
31 Mar 240-613043
31 Dec 230-713347
30 Sep 230-693551
30 Jun 230-783650
31 Mar 230-643747
31 Dec 22053644
30 Sep 220383641
30 Jun 220182934
31 Mar 220132328
31 Dec 210-351622
30 Sep 210-61816
30 Jun 210-19613
31 Mar 210-15411
31 Dec 200-13310

Quality Earnings: RBOT is currently unprofitable.

Growing Profit Margin: RBOT is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: RBOT is unprofitable, and losses have increased over the past 5 years at a rate of 35.8% per year.

Accelerating Growth: Unable to compare RBOT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RBOT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (12.9%).


Return on Equity

High ROE: RBOT has a negative Return on Equity (-107.82%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 07:32
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vicarious Surgical Inc. is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael GormanBTIG
Matthew MiksicCredit Suisse
Adam MaederPiper Sandler Companies